Momelotinib (Ojjaara)

Canada’s Drug Agency (CDA-AMC) recommends that Ojjaara be reimbursed by public drug plans for the treatment of adult patients with intermediate or high-risk primary myelofibrosis (MF), post–polycythemia vera MF, or post–essential thrombocythemia MF who have moderate to severe anemia. Ojjaara should only be covered to treat splenomegaly and/or disease-related symptoms in adult patients with intermediate or high-risk primary MF, post–polycythemia vera MF, or post–essential thrombocythemia MF, who have an enlarged spleen that is palpable in physical examination and at least 5 cm below the rib cage margin, moderate to severe anemia, and good performance status. Ojjaara should only be reimbursed if it is prescribed by specialists in treating MF and the cost of Ojjaara does not exceed the drug program cost of treatment with the least costly Janus kinase inhibitor (JAKi) reimbursed for the treatment of adults with MF.